Review
doi: 10.1517/14712598.1.6.995.
Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA
Affiliations
- PMID: 11728231
- DOI: 10.1517/14712598.1.6.995
Item in Clipboard
Review
Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA
Expert Opin Biol Ther.
2001 Nov.
Abstract
The approval of antibodies for cancer treatment has provoked increased interest in the development of new and improved antibody-mediated therapies. This emerging approach centres on targeting CD22 on human B-cells with a monoclonal antibody (mAb). Anti-CD22 antibodies conjugated to a cytotoxic RNAse elicits potent and specific killing of the lymphoma cells in vitro and in human lymphoma models in severe combined immune deficiency (SCID) mice. RNA damage caused by RNAses could be an important alternative to standard DNA damaging chemotherapeutics. Moreover, targeted RNAses may overcome problems of toxicity and immunogenicity associated with plant- or bacterial toxin-containing immunotoxins.
Similar articles
-
Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents.Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):79-86. doi: 10.1016/s1040-8428(01)00116-0. Crit Rev Oncol Hematol. 2001. PMID: 11418304 Review.
-
Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeutics.Leuk Lymphoma. 2002 May;43(5):953-9. doi: 10.1080/10428190290021380. Leuk Lymphoma. 2002. PMID: 12148905 Review.
-
Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma.Blood. 2001 Jan 15;97(2):528-35. doi: 10.1182/blood.v97.2.528. Blood. 2001. PMID: 11154233
-
Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins.Leukemia. 2003 Feb;17(2):334-8. doi: 10.1038/sj.leu.2402790. Leukemia. 2003. PMID: 12592332
-
Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.Cancer Immunol Immunother. 2005 Jan;54(1):11-24. doi: 10.1007/s00262-004-0572-2. Cancer Immunol Immunother. 2005. PMID: 15693135 Free PMC article.
Cited by
-
Antibodies against G-protein coupled receptors: novel uses in screening and drug development.Comb Chem High Throughput Screen. 2008 Jul;11(6):463-7. doi: 10.2174/138620708784911465. Comb Chem High Throughput Screen. 2008. PMID: 18673273 Free PMC article. Review.
-
The nuclear transport capacity of a human-pancreatic ribonuclease variant is critical for its cytotoxicity.Invest New Drugs. 2011 Oct;29(5):811-7. doi: 10.1007/s10637-010-9426-2. Epub 2010 Mar 30. Invest New Drugs. 2011. PMID: 20352290
-
Immune Modulation by Human Secreted RNases at the Extracellular Space.Front Immunol. 2018 May 16;9:1012. doi: 10.3389/fimmu.2018.01012. eCollection 2018. Front Immunol. 2018. PMID: 29867984 Free PMC article. Review.
-
Use of antibodies and immunoconjugates for the therapy of more accessible cancers.Adv Drug Deliv Rev. 2008 Sep;60(12):1407-20. doi: 10.1016/j.addr.2008.04.011. Epub 2008 Apr 24. Adv Drug Deliv Rev. 2008. PMID: 18508155 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
